Discover AstraZeneca's Enhertu's promising trial results for HER2-positive early breast cancer, showcasing significant survival improvements and plans for regulatory approval.
AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.
Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.